biotech.today

Details

  • ●Modalities: small molecules (RNA-targeting)
  • ●Therapeutic areas: oncology, rare disease
  • ●Key targets: various RNA targets
  • ●Indications: Undisclosed
  • ●Funding: $190M

Partners & investors

  • Roche· Investor

Key considerations

  • ●AI tools in use: mRNA-NEST Platform
  • ●$190M Series C (2023)
  • ●Roche $190M upfront partnership (2024)
Get live updates on Arrakis Therapeutics’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Michael Gilman

Co-Founder & CEO

rna-drug-discovery
Visit website →LinkedIn →